EU Approves Incyte's Opzelura as First Steroid-Free Topical JAK for Atopic Dermatitis
INCY sits 71% above its 52-week low of $69.695 on elevated volume (3.3× avg).
Summary
The European Commission approved Opzelura cream for moderate atopic dermatitis in adults, making it the first steroid-free topical JAK inhibitor cleared for this indication in the EU. The approval expands Opzelura's European label beyond non-segmental vitiligo and opens a market where up to 7% of adults are affected. It follows a positive CHMP opinion in June and is supported by Phase 3b data showing significant itch relief as early as Day 2 and durable responses through 24 weeks. This comes on the heels of Incyte's strong Q2 report and raised guidance, adding a new growth driver in Europe. The company now has two approved indications for Opzelura in the EU, strengthening its dermatology franchise.
Updates
· Wiseek News — Analysts at Guggenheim, HC Wainwright, Barclays, and Leerink raised price targets to $139–$155 following the approval.
At the time of this announcement, INCY was trading at $119.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26B. The 52-week trading range was $69.70 to $132.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.